Document is current

Article History

Accepted: 18 June 2025

First Online: 3 September 2025

Declarations

:

: This study did not receive any funding.

: The authors have no competing interests to declare that are relevant to the content of this study. At the time of the study, all authors were employed by the Medicines and Healthcare products Regulatory Agency (MHRA), which is an Executive Agency of the UK Department of Health and Social Care (DHSC). The MHRA has statutory responsibility to monitor the safety of medicinal products on the UK market, and the study was undertaken independently of the Department of Health and Social Care.

: All data generated or analysed during this study are included in this published article (and its supplementary information files). The Agency provides information to the public in line with requirements of the Freedom of Information Act. In addition, organisations and individuals can apply for Yellow Card data for research purposes. Applications include provision of a protocol and will be considered by the UK Commission of Human Medicine's (CHM) Pharmacovigilance Expert Advisory Group.

: No ethical approval was required. Research Ethics Committee of UK Health Research Authority (HRA) waived ethical approval for this work. No identifiable information about individuals was disclosed in the manuscript and all findings are reported in aggregated form.

: Not applicable.

: Not applicable.

: Not applicable.

: PT, KH, TJ and KD were involved in the design and implementation of the YCVM. TJ extracted the data from the YCVM platform for this study. JW conducted the analysis of the data and with critical input from KD. All authors were involved in the interpretation of the data analysis. The first draft of the manuscript was written by JW and KD. All authors reviewed and contributed to further drafts and had approved the final version of the manuscript.